Faculty
Peter Westervelt.jpg

Peter Westervelt, MD, PhD

Professor
Department of Medicine
Oncology Division
Bone Marrow Transplantation & Leukemia

Clinical Interests

  • Treatment of AML and MDS

Contact

  • 314-454-8323 (tel)
  • 314-454-7551 (fax)
  • 11th Floor Mid-Campus Center (office)
  • Division of Oncology
    Campus Box 8007
    Washington University Medical School
    660 South Euclid Avenue
    St. Louis, MO 63110

Peer-reviewed Manuscripts

  • Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy
    Uy GL, Duncavage EJ, Chang GS, Jacoby MA, Miller CA, Shao J, Heath S, Elliott K, Reineck T, Fulton RS, Fronick CC, O'Laughlin M, Ganel L, Abboud CN, Cashen AF, DiPersio JF, Wilson RK, Link DC, Welch JS, Ley TJ, Graubert TA, Westervelt P, Walter MJ
    Leukemia 2017 Apr;31(4):872-881
  • Fresh or cryopreserved CD34+-selected mobilized peripheral blood stem and progenitor cells for the treatment of poor graft function following allogeneic hematopoietic cell transplantation
    Ghobadi A, Fiala MA, Ramsingh G, Gao F, Abboud CN, Stockerl-Goldstein K, Uy GL, Grossman BJ, Westervelt P, DiPersio JF
    Biol Blood Marrow Transplant 2017 Mar 17; [Epub ahead of print]
  • Donor-derived smoldering multiple myeloma following a hematopoietic cell transplantation for AML
    Fakhri B, Fiala M, Slade M, Westervelt P, Ghobadi A
    Case Rep Hematol 2017;2017:3728429
  • Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft
    Schroeder MA, Rettig MP, Lopez S, Christ S, Fiala M, Eades W, Mir FA, Shao J, McFarland K, Trinkaus K, Shannon W, Deych E, Yu J, Vij R, Stockerl-Goldstein K, Cashen AF, Uy GL, Abboud CN, Westervelt P, DiPersio JF
    Blood 2017 Mar 14; [Epub ahead of print]
  • CpG island hypermethylation mediated by DNMT3A is a consequence of AML progression
    Spencer DH, Russler-Germain DA, Ketkar S, Helton NM, Lamprecht TL, Fulton RS, Fronick CC, O'Laughlin M, Heath SE, Shinawi M, Westervelt P, Payton JE, Wartman LD, Welch JS, Wilson RK, Walter MJ, Link DC, DiPersio JF, Ley TJ
    Cell 2017 Feb 23;168(5):801-816
  • T cell-replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplantation cyclophosphamide results in outcomes similar to transplantation from traditionally matched donors in active disease acute myeloid leukemia
    How J, Slade M, Vu K, DiPersio JF, Westervelt P, Uy GL, Abboud CN, Vij R, Schroeder MA, Fehniger TA, Romee R
    Biol Blood Marrow Transplant 2017 Apr;23(4):648-653
  • Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy
    Duncavage EJ, Uy GL, Petti AA, Miller CA, Lee YS, Tandon B, Gao F, Fronick CC, O'Laughlin M, Fulton RS, Wilson RK, Jacoby MA, Cashen AF, Wartman LD, Walter MJ, Westervelt P, Link DC, DiPersio JF, Ley TJ, Welch JS
    Blood 2017 Mar 9;129(10):1397-1401
  • A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia
    Uy GL, Rettig MP, Stone RM, Konopleva MY, Andreeff M, McFarland K, Shannon W, Fletcher TR, Reineck T, Eades W, Stockerl-Goldstein K, Abboud CN, Jacoby MA, Westervelt P, DiPersio JF
    Blood Cancer J 2017 Mar 10;7(3):e542
  • Cardiomyopathy in patients after posttransplant cyclophosphamide-based hematopoietic cell transplantation
    Lin CJ, Vader JM, Slade M, DiPersio JF, Westervelt P, Romee R
    Cancer 2017 Mar 6; [Epub ahead of print]
  • Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation
    Slade M, Goldsmith S, Romee R, DiPersio JF, Dubberke ER, Westervelt P, Uy GL, Lawrence SJ
    Transpl Infect Dis 2017 Feb;19(1):e12629
  • Single institution experience with G-CSF mobilized T-cell replete haploidentical hematopoietic cell transplantation
    Huselton E, Slade M, DiPersio JF, Westervelt P, Vij R, Uy GL, Fehniger TA, Abboud CN, Gao F, Schroeder MA, Romee R
    Bone Marrow Transplant 2017 Jan 9; [Epub ahead of print]
  • Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology
    Greenberg PL, Stone RM, Al-Kali A, Barta SK, Bejar R, Bennett JM, Carraway H, De Castro CM, Deeg HJ, DeZern AE, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Horsfall R, Johnson RA, Juckett M, Klimek VM, Komrokji R, Kujawski LA, Maness LJ, O'Donnell MR, Pollyea DA, Shami PJ, Stein BL, Walker AR, Westervelt P, Zeidan A, Shead DA, Smith C
    J Natl Compr Canc Netw 2017 Jan;15(1):60-87
  • A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation
    Magenau J, Westervelt P, Khaled S, McGuirk J, Hari P, Eapen M, Becker PS, Parkin B, Braun T, Logan B, Wang H, Jagasia M, Rowley SD, Kim DD, Schechter T, Frey N, Scott B, Churay T, Lieland S, Forman S, Mineishi S
    Bone Marrow Transplant 2017 Jan;52(1):59-65
  • TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes
    Welch JS, Petti AA, Miller CA, Fronick CC, O'Laughlin M, Fulton RS, Wilson RK, Baty JD, Duncavage EJ, Tandon B, Lee YS, Wartman LD, Uy GL, Ghobadi A, Tomasson MH, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, Cashen AF, Schroeder MA, Jacoby MA, Heath SE, Luber K, Janke MR, Hantel A, Khan N, Sukhanova MJ, Knoebel RW, Stock W, Graubert TA, Walter MJ, Westervelt P, Link DC, DiPersio JF, Ley TJ
    N Engl J Med 2016 Nov 24;375(21):2023-2036
  • Comparison of patient-reported outcomes in 5-year survivors who received bone marrow vs peripheral blood unrelated donor transplantation: long-term follow-up of a randomized clinical trial
    Lee SJ, Logan B, Westervelt P, Cutler C, Woolfrey A, Khan SP, Waller EK, Maziarz RT, Wu J, Shaw BE, Confer D, Horowitz MM, Anasetti C
    JAMA Oncol 2016 Dec 1;2(12):1583-1589
  • Targeted sequencing informs the evaluation of normal karyotype cytopenic patients for low-grade myelodysplastic syndrome
    Duncavage EJ, O'Brien J, Vij K, Miller CA, Chang GS, Shao J, Jacoby MA, Heath S, Janke MR, Elliott K, Fulton RS, Fronick C, O'Laughlin M, Westervelt P, Ley TJ, Wilson RK, Walter MJ
    Leukemia 2016 Dec;30(12):2422-2426
  • Post-transplant high-dose cyclophosphamide after HLA-matched vs haploidentical hematopoietic cell transplantation for AML
    Rashidi A, Slade M, DiPersio JF, Westervelt P, Vij R, Romee R
    Bone Marrow Transplant 2016 Dec;51(12):1561-1564
  • Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide
    Goldsmith SR, Slade M, DiPersio JF, Westervelt P, Lawrence SJ, Uy GL, Abboud CN, Vij R, Schroeder MA, Fehniger TA, Dubberke ER, Trinkaus K, Romee R
    Haematologica 2016 Nov;101(11):e465-e468
  • HLA disparity is not inconsequential in peripheral blood T-replete haploidentical hematopoietic stem cell transplantation
    Rashidi A, DiPersio JF, Westervelt P, Abboud CN, Schroeder MA, Pusic I, Cashen AF, Fehniger TA, Romee R
    Bone Marrow Transplant 2016 Sep;51(9):1275-8
  • Do adults aged 70 years or older with acute myeloid leukemia benefit from allogeneic hematopoietic cell transplantation?
    Rashidi A, DiPersio JF, Westervelt P, Vij R, Abboud CN, Romee R
    Leukemia 2016 Aug;30(8):1797-9
  • Acute myeloid leukemia presenting with extensive bone marrow necrosis, leukemia cutis and testicular involvement: successful treatment with allogeneic hematopoietic stem cell transplantation
    Rashidi A, DiPersio JF, Westervelt P, Abboud CN, Romee R
    Bone Marrow Transplant 2016 Mar;51(3):454-5
  • Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation
    Ghobadi A, Choi J, Fiala MA, Fletcher T, Liu J, Eissenberg LG, Abboud C, Cashen A, Vij R, Schroeder MA, Pusic I, Stockerl-Goldstein K, Jacoby M, Uy G, DiPersio J, Westervelt P
    Leuk Res 2016 Oct;49:1-6
  • Severe cytokine-release syndrome after T cell-replete peripheral blood haploidentical donor transplantation is associated with poor survival and anti-IL-6 therapy is safe and well tolerated
    Abboud R, Keller J, Slade M, DiPersio JF, Westervelt P, Rettig MP, Meier S, Fehniger TA, Abboud CN, Uy GL, Vij R, Trinkaus KM, Schroeder MA, Romee R
    Biol Blood Marrow Transplant 2016 Oct;22(10):1851-60
  • Comparison of outcomes after peripheral blood haploidentical versus matched unrelated donor allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia: a retrospective single-center review
    Rashidi A, DiPersio JF, Westervelt P, Vij R, Schroeder MA, Cashen AF, Fehniger TA, Romee R
    Biol Blood Marrow Transplant 2016 Sep;22(9):1696-701
  • Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia
    Griffith M, Griffith OL, Krysiak K, Skidmore ZL, Christopher MJ, Klco JM, Ramu A, Lamprecht TL, Wagner AH, Campbell KM, Lesurf R, Hundal J, Zhang J, Spies NC, Ainscough BJ, Larson DE, Heath SE, Fronick C, O'Laughlin S, Fulton RS, Magrini V, McGrath S, Smith SM, Miller CA, Maher CA, Payton JE, Walker JR, Eldred JM, Walter MJ, Link DC, Graubert TA, Westervelt P, Kulkarni S, DiPersio JF, Mardis ER, Wilson RK, Ley TJ
    Exp Hematol 2016 Jul;44(7):603-13
  • A common founding clone with TP53 and PTEN mutations gives rise to a concurrent germ cell tumor and acute megakaryoblastic leukemia
    Lu C, Riedell P, Miller CA, Hagemann IS, Westervelt P, Ozenberger BA, O'Laughlin M, Magrini V, Demeter RT, Duncavage EJ, Griffith M, Griffith OL, Wartman LD
    Cold Spring Harb Mol Case Stud 2016 Jan;2(1):a000687
  • A study of high-dose lenalidomide induction and low-dose lenalidomide maintenance therapy for patients with hypomethylating agent refractory myelodysplastic syndrome
    Cherian MA, Tibes R, Gao F, Fletcher T, Fiala M, Uy GL, Westervelt P, Jacoby MA, Cashen AF, Stockerl-Goldstein K, DiPersio JF, Vij R
    Leuk Lymphoma 2016 Nov;57(11):2535-2540
  • Chemotherapy versus hypomethylating agents for the treatment of relapsed acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplant
    Motabi IH, Ghobadi A, Liu J, Schroeder M, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Uy GL, Vij R, Westervelt P, DiPersio JF
    Biol Blood Marrow Transplant 2016 Jul;22(7):1324-9
  • Peritransplant serum albumin decline predicts subsequent severe acute graft-versus-host disease after mucotoxic myeloablative conditioning
    Rashidi A, DiPersio JF, Westervelt P, Abboud CN, Schroeder MA, Cashen AF, Pusic I, Romee R
    Biol Blood Marrow Transplant 2016 Jun;22(6):1137-41
  • A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia
    Wartman LD, Fiala MA, Fletcher T, Hawkins ER, Cashen A, DiPersio JF, Jacoby MA, Stockerl-Goldstein KE, Pusic I, Uy GL, Westervelt P, Vij R
    Leuk Lymphoma 2016 Mar;57(3):728-730
  • Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML
    Wong TN, Miller CA, Klco JM, Petti A, Demeter R, Helton NM, Li T, Fulton RS, Heath SE, Mardis ER, Westervelt P, DiPersio JF, Walter MJ, Welch JS, Graubert TA, Wilson RK, Ley TJ, Link DC
    Blood 2016 Feb 18;127(7):893-7
  • Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia
    Churpek JE, Pyrtel K, Kanchi KL, Shao J, Koboldt D, Miller CA, Shen D, Fulton R, O'Laughlin M, Fronick C, Pusic I, Uy GL, Braunstein EM, Levis M, Ross J, Elliott K, Heath S, Jiang A, Westervelt P, DiPersio JF, Link DC, Walter MJ, Welch J, Wilson R, Ley TJ, Godley LA, Graubert TA
    Blood 2015 Nov 26;126(22):2484-90
  • Targeting bone marrow lymphoid niches in acute lymphoblastic leukemia
    Uy GL, Hsu YM, Schmidt AP, Stock W, Fletcher TR, Trinkaus KM, Westervelt P, DiPersio JF, Link DC
    Leuk Res 2015 Dec;39(12):1437-42
  • Maintenance therapy with decitabine after allogeneic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome
    Pusic I, Choi J, Fiala MA, Gao F, Holt M, Cashen AF, Vij R, Abboud CN, Stockerl-Goldstein KE, Jacoby MA, Uy GL, Westervelt P, DiPersio JF
    Biol Blood Marrow Transplant 2015 Oct;21(10):1761-9
  • Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia
    Klco JM, Miller CA, Griffith M, Petti A, Spencer DH, Ketkar-Kulkarni S, Wartman LD, Christopher M, Lamprecht TL, Helton NM, Duncavage EJ, Payton JE, Baty J, Heath SE, Griffith OL, Shen D, Hundal J, Chang GS, Fulton R, O'Laughlin M, Fronick C, Magrini V, Demeter RT, Larson DE, Kulkarni S, Ozenberger BA, Welch JS, Walter MJ, Graubert TA, Westervelt P, Radich JP, Link DC, Mardis ER, DiPersio JF, Wilson RK, Ley TJ
    JAMA 2015 Aug 25;314(8):811-822
  • Hematologic recovery after pretransplant chemotherapy does not influence survival after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients
    Vu K, Manjappa S, DiPersio JF, Gao F, Westervelt P, Vij R, Stockerl-Goldstein KE, Uy GL, Abboud CN, Schroeder MA, Fehniger TA, Cashen AF, Romee R
    Biol Blood Marrow Transplant 2015 Aug;21(8):1425-30
  • Myelodysplastic syndromes, version 2.2015
    Greenberg PL, Stone RM, Bejar R, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, DeZern AE, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Klimek V, Komrokji R, Kujawski LA, Maness LJ, O'Donnell MR, Pollyea DA, Scott B, Shami PJ, Stein BL, Westervelt P, Wheeler B, Shead DA, Smith C
    J Natl Compr Canc Netw 2015 Mar;13(3):261-72
  • Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia
    Wong TN, Ramsingh G, Young AL, Miller CA, Touma W, Welch JS, Lamprecht TL, Shen D, Hundal J, Fulton RS, Heath S, Baty JD, Klco JM, Ding L, Mardis ER, Westervelt P, DiPersio JF, Walter MJ, Graubert TA, Ley TJ, Druley TE, Link DC, Wilson RK
    Nature 2015 Feb 26;518(7540):552-555
  • Caspase-9 is required for normal hematopoietic development and protection from alkylator-induced DNA damage in mice
    Lu EP, McLellan M, Ding L, Fulton R, Mardis ER, Wilson RK, Miller CA, Westervelt P, DiPersio JF, Link DC, Walter MJ, Ley TJ, Graubert TA
    Blood 2014 Dec 18;124(26):3887-95
  • Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802
    Bolanos-Meade J, Logan BR, Alousi AM, Antin JH, Barowski K, Carter SL, Goldstein SC, Hexner EO, Horowitz MM, Lee SJ, Levine JE, MacMillan ML, Martin PJ, Mendizabal AM, Nakamura R, Pasquini MC, Weisdorf DJ, Westervelt P, Ho VT
    Blood 2014 Nov 20;124(22):3221-7
  • A phase II study of V-BEAM as conditioning regimen before second auto-SCT for multiple myeloma
    Wang TF, Fiala MA, Cashen AF, Uy GL, Abboud CN, Fletcher T, Wu N, Westervelt P, DiPersio JF, Stockerl-Goldstein KE, Vij R
    Bone Marrow Transplant 2014 Nov;49(11):1366-70
  • Clonal architecture of secondary acute myeloid leukemia defined by single-cell sequencing
    Hughes AE, Magrini V, Demeter R, Miller CA, Fulton R, Fulton LL, Eades WC, Elliott K, Heath S, Westervelt P, Ding L, Conrad DF, White BS, Shao J, Link DC, DiPersio JF, Mardis ER, Wilson RK, Ley TJ, Walter MJ, Graubert TA
    PLoS Genet 2014 Jul 10;10(7):e1004462
  • An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes
    Goldberg SL, Fenaux P, Craig MD, Gyan E, Lister J, Kassis J, Pigneux A, Schiller GJ, Jung J, Jane Leonard E, Fingert H, Westervelt P
    Leuk Res Rep 2014 Jul 5;3(2):58-61
  • Haploidentical transplantation using G-CSF-mobilized T-cell replete PBSCs and post-transplantation CY after non-myeloablative conditioning is safe and is associated with favorable outcomes
    Bhamidipati PK, DiPersio JF, Stockerl-Goldstein K, Rashidi A, Gao F, Uy GL, Westervelt P, Vij R, Schroeder MA, Abboud CN, Keller JW, Fehniger TA, Romee R
    Bone Marrow Transplant 2014 Aug;49(8):1124-6
  • A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML
    Welch JS, Niu H, Uy GL, Westervelt P, Abboud CN, Vij R, Stockerl-Goldstein KE, Jacoby M, Pusic I, Schroeder MA, DiPersio JF, Cashen AF
    Am J Hematol 2014 Aug;89(8):E103-8
  • Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML
    Ramsingh G, Westervelt P, McBride A, Stockerl-Goldstein K, Vij R, Fiala M, Uy G, Cashen A, DiPersio JF, Abboud CN
    Int J Hematol 2014 Mar;99(3):272-8
  • Phase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia
    Jacoby MA, Martin MG, Uy GL, Westervelt P, DiPersio JF, Cashen A, Stockerl-Goldstein K, Vij R, Luo J, Reineck T, Bernabe N, Abboud CN
    Am J Hematol 2014 May;89(5):487-92
  • Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen
    Manjappa S, Bhamidipati PK, Stokerl-Goldstein KE, DiPersio JF, Uy GL, Westervelt P, Liu J, Schroeder MA, Vij R, Abboud CN, Fehniger TA, Cashen AF, Pusic I, Jacoby M, Meera SJ, Romee R
    Biol Blood Marrow Transplant 2014 Jan;20(1):46-52
  • Myeloid growth factors
    Crawford J, Armitage J, Balducci L, Becker PS, Blayney DW, Cataland SR, Heaney ML, Hudock S, Kloth DD, Kuter DJ, Lyman GH, McMahon B, Rugo HS, Saad AA, Schwartzberg LS, Shayani S, Steensma DP, Talbott M, Vadhan-Raj S, Westervelt P, Westmoreland M, Dwyer M, Ho M
    J Natl Compr Canc Netw 2013 Oct 1;11(10):1266-90
  • Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia
    Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson A, Hoadley K, Triche TJ Jr, Laird PW, Baty JD, Fulton LL, Fulton R, Heath SE, Kalicki-Veizer J, Kandoth C, Klco JM, Koboldt DC, Kanchi KL, Kulkarni S, Lamprecht TL, Larson DE, Lin L, Lu C, McLellan MD, McMichael JF, Payton J, Schmidt H, Spencer DH, Tomasson MH, Wallis JW, Wartman LD, Watson MA, Welch J, Wendl MC, Ally A, Balasundaram M, Birol I, Butterfield Y, Chiu R, Chu A, Chuah E, Chun HJ, Corbett R, Dhalla N, Guin R, He A, Hirst C, Hirst M, Holt RA, Jones S, Karsan A, Lee D, Li HI, Marra MA, Mayo M, Moore RA, Mungall K, Parker J, Pleasance E, Plettner P, Schein J, Stoll D, Swanson L, Tam A, Thiessen N, Varhol R, Wye N, Zhao Y, Gabriel S, Getz G, Sougnez C, Zou L, Leiserson MD, Vandin F, Wu HT, Applebaum F, Baylin SB, Akbani R, Broom BM, Chen K, Motter TC, Nguyen K, Weinstein JN, Zhang N, Ferguson ML, Adams C, Black A, Bowen J, Gastier-Foster J, Grossman T, Lichtenberg T, Wise L, Davidsen T, Demchok JA, Shaw KR, Sheth M, Sofia HJ, Yang L, Downing JR, Eley G, Alonso S, Ayala B, Baboud J, Backus M, Barletta SP, Berton DL, Chu AL, Girshik S, Jensen MA, Kahn A, Kothiyal P, Nicholls MC, Pihl TD, Pot DA, Raman R, Sanbhadti RN, Snyder EE, Srinivasan D, Walton J, Wan Y, Wang Z, Issa JP, Le Beau M, Carroll M, Kantarjian H, Kornblau S, Bootwalla MS, Lai PH, Shen H, Van Den Berg DJ, Weisenberger DJ, Link DC, Walter MJ, Ozenberger BA, Mardis ER, Westervelt P, Graubert TA, DiPersio JF, Wilson RK
    N Engl J Med 2013 May 30;368(22):2059-74
  • Comparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndrome
    McBride A, Lathon SC, Boehmer L, Augustin KM, Butler SK, Westervelt P
    Pharmacotherapy 2013 Mar;33(3):295-303
  • Clonal diversity of recurrently mutated genes in myelodysplastic syndromes
    Walter MJ, Shen D, Shao J, Ding L, White BS, Kandoth C, Miller CA, Niu B, McLellan MD, Dees ND, Fulton R, Elliot K, Heath S, Grillot M, Westervelt P, Link DC, DiPersio JF, Mardis E, Ley TJ, Wilson RK, Graubert TA
    Leukemia 2013 Jun;27(6):1275-82
  • A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML
    Ramsingh G, Westervelt P, Cashen AF, Uy GL, Stockerl-Goldstein K, Abboud CN, Bernabe N, Monahan R, DiPersio JF, Vij R
    Leukemia 2013 Mar;27(3):725-8
  • Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: Results of Cancer and Leukemia Group B Study 19802
    Stock W, Johnson JL, Stone RM, Kolitz JE, Powell BL, Wetzler M, Westervelt P, Marcucci G, Deangelo DJ, Vardiman JW, McDonnell D, Mrozek K, Bloomfield CD, Larson RA
    Cancer 2013 Jan 1;119(1):90-8
  • Myelodysplastic syndromes: clinical practice guidelines in oncology
    Greenberg PL, Attar E, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, Frankfurt O, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, O'Donnell MR, Shami PJ, Stein BL, Stone RM, Thompson JE, Westervelt P, Wheeler B, Shead DA, Naganuma M
    J Natl Compr Canc Netw 2013 Jul;11(7):838-74
  • Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies
    McBride A, Westervelt P
    J Hematol Oncol 2012 Dec 13;5:75
  • Peripheral-blood stem cells versus bone marrow from unrelated donors
    Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, Cutler CS, Westervelt P, Woolfrey A, Couban S, Ehninger G, Johnston L, Maziarz RT, Pulsipher MA, Porter DL, Mineishi S, McCarty JM, Khan SP, Anderlini P, Bensinger WI, Leitman SF, Rowley SD, Bredeson C, Carter SL, Horowitz MM, Confer DL
    N Engl J Med 2012 Oct 18;367(16):1487-96
  • The origin and evolution of mutations in acute myeloid leukemia
    Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC, Wartman LD, Lamprecht TL, Liu F, Xia J, Kandoth C, Fulton RS, McLellan MD, Dooling DJ, Wallis JW, Chen K, Harris CC, Schmidt HK, Kalicki-Veizer JM, Lu C, Zhang Q, Lin L, O'Laughlin MD, McMichael JF, Delehaunty KD, Fulton LA, Magrini VJ, McGrath SD, Demeter RT, Vickery TL, Hundal J, Cook LL, Swift GW, Reed JP, Alldredge PA, Wylie TN, Walker JR, Watson MA, Heath SE, Shannon WD, Varghese N, Nagarajan R, Payton JE, Baty JD, Kulkarni S, Klco JM, Tomasson MH, Westervelt P, Walter MJ, Graubert TA, Dipersio JF, Ding L, Mardis ER, Wilson RK
    Cell 2012 Jul 20;150(2):264-78
  • Clonal architecture of secondary acute myeloid leukemia
    Walter MJ, Shen D, Ding L, Shao J, Koboldt DC, Chen K, Larson DE, McLellan MD, Dooling D, Abbott R, Fulton R, Magrini V, Schmidt H, Kalicki-Veizer J, O'Laughlin M, Fan X, Grillot M, Witowski S, Heath S, Frater JL, Eades W, Tomasson M, Westervelt P, DiPersio JF, Link DC, Mardis ER, Ley TJ, Wilson RK, Graubert TA
    N Engl J Med 2012 Mar 22;366(12):1090-8
  • Silybum marianum (milk thistle) in the management and prevention of hepatotoxicity in a patient undergoing reinduction therapy for acute myelogenous leukemia
    McBride A, Augustin KM, Nobbe J, Westervelt P
    J Oncol Pharm Pract 2012 Sep;18(3):360-5
  • A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia
    Uy GL, Rettig MP, Motabi IH, McFarland K, Trinkaus KM, Hladnik LM, Kulkarni S, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Vij R, Westervelt P, DiPersio JF
    Blood 2012 Apr 26;119(17):3917-24
  • Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
    Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, Ritchey JK, Young MA, Lamprecht T, McLellan MD, McMichael JF, Wallis JW, Lu C, Shen D, Harris CC, Dooling DJ, Fulton RS, Fulton LL, Chen K, Schmidt H, Kalicki-Veizer J, Magrini VJ, Cook L, McGrath SD, Vickery TL, Wendl MC, Heath S, Watson MA, Link DC, Tomasson MH, Shannon WD, Payton JE, Kulkarni S, Westervelt P, Walter MJ, Graubert TA, Mardis ER, Wilson RK, DiPersio JF
    Nature 2012 Jan 11;481(7382):506-10
  • Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature
    Chawla JS, Ghobadi A, Mosley J 3rd, Verkruyse L, Trinkaus K, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Uy GL, Westervelt P, DiPersio JF, Vij R
    Transpl Infect Dis 2012 Jun;14(3):259-67
  • Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes
    Graubert TA, Shen D, Ding L, Okeyo-Owuor T, Lunn CL, Shao J, Krysiak K, Harris CC, Koboldt DC, Larson DE, McLellan MD, Dooling DJ, Abbott RM, Fulton RS, Schmidt H, Kalicki-Veizer J, O'Laughlin M, Grillot M, Baty J, Heath S, Frater JL, Nasim T, Link DC, Tomasson MH, Westervelt P, DiPersio JF, Mardis ER, Ley TJ, Wilson RK, Walter MJ
    Nat Genet 2011 Dec 11;44(1):53-7
  • Myeloid growth factors
    Crawford J, Allen J, Armitage J, Blayney DW, Cataland SR, Heaney ML, Htoy S, Hudock S, Kloth DD, Kuter DJ, Lyman GH, McMahon B, Steensma DP, Vadhan-Raj S, Westervelt P, Westmoreland M
    J Natl Compr Canc Netw 2011 Aug 1;9(8):914-32
  • Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study
    Welch JS, Klco JM, Gao F, Procknow E, Uy GL, Stockerl-Goldstein KE, Abboud CN, Westervelt P, DiPersio JF, Hassan A, Cashen AF, Vij R
    Am J Hematol 2011 Sep;86(9):796-800
  • Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation
    Smeltzer JP, Cashen AF, Zhang Q, Homb A, Dehdashti F, Abboud CN, DiPersio JF, Stockerl-Goldstein KE, Uy GL, Vij R, Westervelt P, Bartlett NL, Fehniger TA
    Biol Blood Marrow Transplant 2011 Nov;17(11):1646-52
  • Rationale and design of the chronic GVHD cohort study: improving outcomes assessment in chronic GVHD
    Chronic GVHD Consortium (Contributors include: Westervelt P)
    Biol Blood Marrow Transplant 2011 Aug;17(8):1114-20
  • Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts
    Brunstein CG, Fuchs EJ, Carter SL, Karanes C, Costa LJ, Wu J, Devine SM, Wingard JR, Aljitawi OS, Cutler CS, Jagasia MH, Ballen KK, Eapen M, O'Donnell PV
    Blood 2011 Jul 14;118(2):282-8
  • Use of whole-genome sequencing to diagnose a cryptic fusion oncogene
    Welch JS, Westervelt P, Ding L, Larson DE, Klco JM, Kulkarni S, Wallis J, Chen K, Payton JE, Fulton RS, Veizer J, Schmidt H, Vickery TL, Heath S, Watson MA, Tomasson MH, Link DC, Graubert TA, DiPersio JF, Mardis ER, Ley TJ, Wilson RK
    JAMA 2011 Apr 20;305(15):1577-1584
  • Recurrent DNMT3A mutations in patients with myelodysplastic syndromes
    Walter MJ, Ding L, Shen D, Shao J, Grillot M, McLellan M, Fulton R, Schmidt H, Kalicki-Veizer J, O'Laughlin M, Kandoth C, Baty J, Westervelt P, DiPersio JF, Mardis ER, Wilson RK, Ley TJ, Graubert TA
    Leukemia 2011 Jul;25(7):1153-8
  • Reduced-Intensity Allogeneic Transplantation Provides High Event-Free and Overall Survival in Patients with Advanced Indolent B Cell Malignancies: CALGB 109901
    Shea T, Johnson J, Westervelt P, Farag S, McCarty J, Bashey A, Isola L, Baxter-Lowe LA, Kelly M, Owzar K, Linker C
    Biol Blood Marrow Transplant 2011 Sep;17(9):1395-403
  • Myelodysplastic syndromes
    Greenberg PL, Attar E, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ, Foran JM, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, Nimer SD, O'Donnell MR, Schroeder MA, Shami PJ, Stone RM, Thompson JE, Westervelt P
    J Natl Compr Canc Netw 2011 Jan;9(1):30-56
  • A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia
    Fehniger TA, Uy GL, Trinkaus K, Nelson AD, Demland J, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Westervelt P, DiPersio JF, Vij R
    Blood 2011 Feb 10;117(6):1828-33
  • Graft-versus-host disease treatment: predictors of survival
    Levine JE, Logan B, Wu J, Alousi AM, Ho V, Bolanos-Meade J, Weisdorf D
    Blood and Marrow Transplant Clinical Trials Network (Contributors include: Westervelt P)

    Biol Blood Marrow Transplant 2010 Dec;16(12):1693-9
  • DNMT3A mutations in acute myeloid leukemia
    Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, Kandoth C, Payton JE, Baty J, Welch J, Harris CC, Lichti CF, Townsend RR, Fulton RS, Dooling DJ, Koboldt DC, Schmidt H, Zhang Q, Osborne JR, Lin L, O'Laughlin M, McMichael JF, Delehaunty KD, McGrath SD, Fulton LA, Magrini VJ, Vickery TL, Hundal J, Cook LL, Conyers JJ, Swift GW, Reed JP, Alldredge PA, Wylie T, Walker J, Kalicki J, Watson MA, Heath S, Shannon WD, Varghese N, Nagarajan R, Westervelt P, Tomasson MH, Link DC, Graubert TA, DiPersio JF, Mardis ER, Wilson RK
    N Engl J Med 2010 Dec 16;363(25):2424-33
  • Use of cytomegalovirus intravenous immune globulin for the adjunctive treatment of cytomegalovirus in hematopoietic stem cell transplant recipients
    Alexander BT, Hladnik LM, Augustin KM, Casabar E, McKinnon PS, Reichley RM, Ritchie DJ, Westervelt P, Dubberke ER
    Pharmacotherapy 2010 Jun;30(6):554-61
  • Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF
    Martin MG, Augustin KM, Uy GL, Welch JS, Hladnik L, Goyal S, Tiwari D, Monahan RS, Reichley RM, Cashen AF, Stockerl-Goldstein K, Westervelt P, Abboud CN, DiPersio JF, Vij R
    Am J Hematol 2009 Nov;84(11):733-7
  • Recurring mutations found by sequencing an acute myeloid leukemia genome
    Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, Koboldt DC, Fulton RS, Delehaunty KD, McGrath SD, Fulton LA, Locke DP, Magrini VJ, Abbott RM, Vickery TL, Reed JS, Robinson JS, Wylie T, Smith SM, Carmichael L, Eldred JM, Harris CC, Walker J, Peck JB, Du F, Dukes AF, Sanderson GE, Brummett AM, Clark E, McMichael JF, Meyer RJ, Schindler JK, Pohl CS, Wallis JW, Shi X, Lin L, Schmidt H, Tang Y, Haipek C, Wiechert ME, Ivy JV, Kalicki J, Elliott G, Ries RE, Payton JE, Westervelt P, Tomasson MH, Watson MA, Baty J, Heath S, Shannon WD, Nagarajan R, Link DC, Walter MJ, Graubert TA, DiPersio JF, Wilson RK, Ley TJ
    N Engl J Med 2009 Sep 10;361(11):1058-66
  • Acquired copy number alterations in adult acute myeloid leukemia genomes
    Walter MJ, Payton JE, Ries RE, Shannon WD, Deshmukh H, Zhao Y, Baty J, Heath S, Westervelt P, Watson MA, Tomasson MH, Nagarajan R, O'Gara BP, Bloomfield CD, Mrozek K, Selzer RR, Richmond TA, Kitzman J, Geoghegan J, Eis PS, Maupin R, Fulton RS, McLellan M, Wilson RK, Mardis ER, Link DC, Graubert TA, DiPersio JF, Ley TJ
    Proc Natl Acad Sci U S A 2009 Aug 4;106(31):12950-5
  • A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes
    Martin MG, Walgren RA, Procknow E, Uy GL, Stockerl-Goldstein K, Cashen AF, Westervelt P, Abboud CN, Kreisel F, Augustin K, DiPersio JF, Vij R
    Am J Hematol 2009 Sep;84(9):560-4
  • Assessment of an alternative meropenem dosing strategy compared with imipenem-cilastatin or traditional meropenem dosing after cefepime failure or intolerance in adults with neutropenic fever
    Arnold HM, McKinnon PS, Augustin KM, Hladnik LM, Casabar E, Reichley RM, Dubberke ER, Westervelt P, Ritchie DJ
    Pharmacotherapy 2009 Aug;29(8):914-23
  • Myeloid growth factors
    Crawford J, Armitage J, Balducci L, Bennett C, Blayney DW, Cataland SR, Dale DC, Demetri GD, Erba HP, Foran J, Freifeld AG, Goemann M, Heaney ML, Htoy S, Hudock S, Kloth DD, Kuter DJ, Lyman GH, Michaud LB, Miyata SC, Tallman MS, Vadhan-Raj S, Westervelt P, Wong MK
    J Natl Compr Canc Netw 2009 Jan;7(1):64-83
  • Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG
    Martin MG, Uy GL, Procknow E, Stockerl-Goldstein K, Cashen A, Westervelt P, Abboud CN, Augustin K, Luo J, DiPersio JF, Vij R
    Bone Marrow Transplant 2009 Jul;44(1):13-7
  • DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome
    Ley TJ, Mardis ER, Ding L, Fulton B, McLellan MD, Chen K, Dooling D, Dunford-Shore BH, McGrath S, Hickenbotham M, Cook L, Abbott R, Larson DE, Koboldt DC, Pohl C, Smith S, Hawkins A, Abbott S, Locke D, Hillier LW, Miner T, Fulton L, Magrini V, Wylie T, Glasscock J, Conyers J, Sander N, Shi X, Osborne JR, Minx P, Gordon D, Chinwalla A, Zhao Y, Ries RE, Payton JE, Westervelt P, Tomasson MH, Watson M, Baty J, Ivanovich J, Heath S, Shannon WD, Nagarajan R, Walter MJ, Link DC, Graubert TA, DiPersio JF, Wilson RK
    Nature 2008 Nov 6;456(7218):66-72
  • Myelodysplastic syndromes
    Greenberg PL, Attar E, Battiwalla M, Bennett JM, Bloomfield CD, Decastro CM, Deeg HJ, Erba HP, Foran JM, Garcia-Manero G, Gore SD, Head D, Maness LJ, Millenson M, Nimer SD, O'Donnell MR, Saba HI, Shami PJ, Spiers K, Stone RM, Tallman MS, Westervelt P
    J Natl Compr Canc Netw 2008 Oct;6(9):902-26
  • Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation
    Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen AF, Westervelt P, Vij R, Abboud CN, Stockerl-Goldstein KE, Sempek DS, Smith AL, DiPersio JF
    Biol Blood Marrow Transplant 2008 Sep;14(9):1045-56
  • Rapid mobilization of functional donor hematopoietic cells without G-CSF using plerixafor, an antagonist of the CXCR4/SDF-1 interaction
    Devine SM, Vij R, Rettig M, Todt L, McGlauchlen K, Fisher N, Devine H, Link DC, Calandra G, Bridger G, Westervelt P, DiPersio JF
    Blood 2008 Aug 15;112(4):990-8
  • Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia
    Tomasson MH, Xiang Z, Walgren R, Zhao Y, Kasai Y, Miner T, Ries RE, Lubman O, Fremont D, McLellan MD, Payton JE, Westervelt P, DiPersio JF, Link DC, Walter MJ, Graubert TA, Watson M, Baty J, Heath S, Shannon WD, Nagarajan R, Bloomfield CD, Mardis ER, Wilson RK, Ley TJ
    Blood 2008 May 1;111(9):4797-808
  • Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia
    Link DC, Kunter G, Kasai Y, Zhao Y, Miner T, McLellan MD, Ries RE, Kapur D, Nagarajan R, Dale DC, Bolyard AA, Boxer LA, Welte K, Zeidler C, Donadieu J, Bellanne-Chantelot C, Vardiman JW, Caligiuri MA, Bloomfield CD, DiPersio JF, Tomasson MH, Graubert TA, Westervelt P, Watson M, Shannon W, Baty J, Mardis ER, Wilson RK, Ley TJ
    Blood 2007 Sep 1;110(5):1648-55
  • Myeloid growth factors
    Crawford J, Althaus B, Armitage J, Balducci L, Bennett C, Blayney DW, Cataland SR, Dale DC, Demetri GD, Erba HP, Foran J, Freifeld AG, Heaney ML, Htoy S, Kloth DD, Lyman GH, Messersmith WA, Michaud LB, Miyata SC, Robbins A, Tallman MS, Vadhan-Raj S, Westervelt P, Wong MK
    J Natl Compr Canc Netw 2007 Feb;5(2):188-202
  • Clinical response of myelodysplastic syndromes patients to treatment with coenzyme Q10
    Galili N, Sechman EV, Cerny J, Mehdi M, Mumtaz M, Westervelt P, Maguire J, Raza A
    Leuk Res 2007 Jan;31(1):19-26
  • Can molecular profiling of cytogenetic subgroups draw a roadmap for individualizing therapy in myelodysplastic syndromes?
    Galili NB, Mehdi M, Mumtaz M, Miron P, Woda B, Al-Homsi S, Westervelt P, Raza A
    Future Oncol 2006 Jun;2(3):407-15
  • Cellular immune therapy for refractory cancers: novel therapeutic strategies
    Ballen KK, Colvin G, Dey BR, Porter D, Westervelt P, Spitzer TR, Quesenberry PJ
    Exp Hematol 2005 Dec;33(12):1427-35
  • A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease
    Carpenter PA, Lowder J, Johnston L, Frangoul H, Khoury H, Parker P, Jerome KR, McCune JS, Storer B, Martin P, Appelbaum F, Abonour R, Westervelt P, Anasetti C
    Biol Blood Marrow Transplant 2005 Jun;11(6):465-71
  • High-penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARalpha expression
    Westervelt P, Lane AA, Pollock JL, Oldfather K, Holt MS, Zimonjic DB, Popescu NC, DiPersio JF, Ley TJ
    Blood 2003 Sep 1;102(5):1857-65
  • High-dose cyclophosphamide, BCNU, and VP-16 (CBV) conditioning before allogeneic stem cell transplantation for patients with non-Hodgkin's lymphoma
    Rossi HA, Becker PS, Emmons RV, Westervelt P, Levy W, Liu Q, Clark Y, Ballen K
    Bone Marrow Transplant 2003 Mar;31(6):441-6
  • Low-dose (550 cGy), single-exposure total body irradiation and cyclophosphamide: consistent, durable engraftment of related-donor peripheral blood stem cells with low treatment-related mortality and fatal organ toxicity
    Blum W, Brown R, Lin HS, Zehnbauer B, Khoury H, Goodnough LT, Westervelt P, Vij R, DiPersio J, Adkins D
    Biol Blood Marrow Transplant 2002;8(11):608-18
  • Adaptive immunity cooperates with liposomal all-trans-retinoic acid (ATRA) to facilitate long-term molecular remissions in mice with acute promyelocytic leukemia
    Westervelt P, Pollock JL, Oldfather KM, Walter MJ, Ma MK, Williams A, DiPersio JF, Ley TJ
    Proc Natl Acad Sci U S A 2002 Jul 9;99(14):9468-73
  • Pharmacokinetic study of infusional valspodar
    Ma MK, McLeod HL, Westervelt P, Fracasso PM
    J Clin Pharmacol 2002 Apr;42(4):412-8
  • Mouse models of acute promyelocytic leukemia
    Pollock JL, Westervelt P, Walter MJ, Lane AA, Ley TJ
    Curr Opin Hematol 2001 Jul;8(4):206-11
  • Immune hemolysis involving non-ABO/RhD alloantibodies following hematopoietic stem cell transplantation
    Young PP, Goodnough LT, Westervelt P, Diersio JF
    Bone Marrow Transplant 2001 Jun;27(12):1305-10
  • Low incidence of transplantation-related acute complications in patients with chronic myeloid leukemia undergoing allogeneic stem cell transplantation with a low-dose (550 cGy) total body irradiation conditioning regimen
    Khoury H, Adkins D, Brown R, Pence H, Vij R, Goodnough LT, Westervelt P, Trinkaus K, Lin HS, DiPersio Y
    Biol Blood Marrow Transplant 2001;7(6):352-8
  • Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin
    Khoury H, Kashyap A, Adkins DR, Brown RA, Miller G, Vij R, Westervelt P, Trinkaus K, Goodnough LT, Hayashi RJ, Parker P, Forman SJ, DiPersio JF
    Bone Marrow Transplant 2001 May;27(10):1059-64
  • Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide
    Westervelt P, Brown RA, Adkins DR, Khoury H, Curtin P, Hurd D, Luger SM, Ma MK, Ley TJ, DiPersio JF
    Blood 2001 Jul 15;98(2):266-71
  • Resolution of psoriasis after allogeneic bone marrow transplantation for chronic myelogenous leukemia: late complications of therapy
    Adkins DR, Abidi MH, Brown RA, Khoury H, Goodnough LT, Vij R, Westervelt P, DiPersio JF
    Bone Marrow Transplant 2000 Dec;26(11):1239-41
  • Acquired, nonrandom chromosomal abnormalities associated with the development of acute promyelocytic leukemia in transgenic mice
    Zimonjic DB, Pollock JL, Westervelt P, Popescu NC, Ley TJ
    Proc Natl Acad Sci U S A 2000 Nov 21;97(24):13306-11
  • Pathologic, cytogenetic and molecular assessment of acute promyelocytic leukemia patients treated with arsenic trioxide (As2O3)
    Zhang T, Westervelt P, Hess JL
    Mod Pathol 2000 Sep;13(9):954-61
  • Adverse side-effects associated with G-CSF in patients with chronic myeloid leukemia undergoing allogeneic peripheral blood stem cell transplantation
    Khoury H, Adkins D, Brown R, Vij R, Westervelt P, Trinkaus K, Goodnough LT, DiPersio JF
    Bone Marrow Transplant 2000 Jun;25(11):1197-201
  • Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies
    Fracasso PM, Westervelt P, Fears CL, Rosen DM, Zuhowski EG, Cazenave LA, Litchman M, Egorin MJ
    J Clin Oncol 2000 Mar;18(5):1124-34
  • A bcr-3 isoform of RARalpha-PML potentiates the development of PML-RARalpha-driven acute promyelocytic leukemia
    Pollock JL, Westervelt P, Kurichety AK, Pelicci PG, Grisolano JL, Ley TJ
    Proc Natl Acad Sci U S A 1999 Dec 21;96(26):15103-8
  • Seed versus soil: the importance of the target cell for transgenic models of human leukemias
    Westervelt P, Ley TJ
    Blood 1999 Apr 1;93(7):2143-8
  • HIV-1 V3 envelope sequences required for macrophage infection
    Henkel T, Westervelt P, Ratner L
    AIDS 1995 Apr;9(4):399-401
  • Role of HIV-1 envelope V3 loop cleavage in cell tropism
    Gu R, Westervelt P, Ratner L
    AIDS Res Hum Retroviruses 1993 Oct;9(10):1007-15
  • Identification of HIV1 determinants for T lymphoid cell line infection
    Carrillo A, Trowbridge DB, Westervelt P, Ratner L
    Virology 1993 Dec;197(2):817-24
  • Structure-function relationships of the HIV-1 envelope V3 loop tropism determinant: evidence for two distinct conformations
    Ebenbichler C, Westervelt P, Carrillo A, Henkel T, Johnson D, Ratner L
    AIDS 1993 May;7(5):639-46
  • Dual regulation of silent and productive infection in monocytes by distinct human immunodeficiency virus type 1 determinants
    Westervelt P, Henkel T, Trowbridge DB, Orenstein J, Heuser J, Gendelman HE, Ratner L
    J Virol 1992 Jun;66(6):3925-31
  • Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo
    Westervelt P, Trowbridge DB, Epstein LG, Blumberg BM, Li Y, Hahn BH, Shaw GM, Price RW, Ratner L
    J Virol 1992 Apr;66(4):2577-82
  • Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes
    Westervelt P, Gendelman HE, Ratner L
    Proc Natl Acad Sci U S A 1991 Apr 15;88(8):3097-101
  • Formation of noninfectious HIV-1 virus particles lacking a full-length envelope protein
    Ratner L, Vander Heyden N, Garcia J, Polinsky M, Westervelt P, Becich M
    AIDS Res Hum Retroviruses 1991 Mar;7(3):287-94
  • Limited sequence heterogeneity among biologically distinct human immunodeficiency virus type 1 isolates from individuals involved in a clustered infectious outbreak
    McNearney T, Westervelt P, Thielan BJ, Trowbridge DB, Garcia J, Whittier R, Ratner L
    Proc Natl Acad Sci U S A 1990 Mar;87(5):1917-21